Influenza Vaccine Effectiveness in the United States During the 2016-2017 Season
Influenza Vaccine Effectiveness in the United States During the 2016-2017 Season
复制标题
DOI：
10.1093/cid/ciy775
复制
发表时间：
2019-06-01
影响因子：
11.8
通讯作者：
Barnes, John
中科院分区：
文献类型：
--
作者：
Flannery, Brendan;Chung, Jessie R.;Barnes, John
背景在最近的流感季节，灭活流感疫苗对甲型（H3N2）流感病毒的有效性低于对甲型（H1N1）pdm09和B流感病毒的有效性，即使在循环病毒与疫苗组分保持抗原相似的情况下。方法在2016 - 2017年流感季节，在美国5个地点的急性呼吸道疾病门诊患者中，使用一种试验检查了不同年龄组和疫苗类型的疫苗有效性（VE），结果在7083名受试者中，甲型H3 N2流感病毒阳性1342例（19%），乙型B流感病毒阳性648例（9（包括B/Yamagata，n = 577），5040例（71%）为流感阴性。疫苗有效率为40%（95%置信区间[CI]，32%至46%），针对任何流感病毒，33%（95% CI，23%至41%），以及53%（95%可信区间，43%至61%）对抗流感B病毒。2017年流感疫苗在门诊患者中对任何流感都提供了适度的保护，但对甲型流感（H3N2）病毒的保护性低于B病毒。2016 - 2017年的流感疫苗对门诊患者的任何流感都提供了适度的保护，但对甲型H3N2流感病毒的保护性低于B病毒。
Background In recent influenza seasons, the effectiveness of inactivated influenza vaccines against circulating A(H3N2) virus has been lower than against A(H1N1)pdm09 and B viruses, even when circulating viruses remained antigenically similar to vaccine components.Methods During the 2016-2017 influenza season, vaccine effectiveness (VE) across age groups and vaccine types was examined among outpatients with acute respiratory illness at 5 US sites using a test-negative design that compared the odds of vaccination among reverse transcription polymerase chain reaction-confirmed influenza positives and negatives.Results Among 7083 enrollees, 1342 (19%) tested positive for influenza A(H3N2), 648 (9%) were positive for influenza B (including B/Yamagata, n = 577), and 5040 (71%) were influenza negative. Vaccine effectiveness was 40% (95% confidence interval [CI], 32% to 46%) against any influenza virus, 33% (95% CI, 23% to 41%) against influenza A(H3N2) viruses, and 53% (95% CI, 43% to 61%) against influenza B viruses.Conclusions The 2016-2017 influenza vaccines provided moderate protection against any influenza among outpatients but were less protective against influenza A(H3N2) viruses than B viruses. Approaches to improving effectiveness against A(H3N2) viruses are needed.The 2016-2017 influenza vaccines provided moderate protection against any influenza among outpatients but were less protective against influenza A(H3N2) viruses than B viruses.